Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Common Equity (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Common Equity for 8 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity changed N/A to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $7.8 million for FY2025, N/A changed from the prior year.
  • Common Equity for Q4 2025 was $7.8 million at Actinium Pharmaceuticals, down from $13.8 million in the prior quarter.
  • The five-year high for Common Equity was $80.5 million in Q2 2021, with the low at $7.8 million in Q4 2025.
  • Average Common Equity over 5 years is $51.2 million, with a median of $53.1 million recorded in 2023.
  • The sharpest move saw Common Equity decreased 2.68% in 2022, then tumbled 63.92% in 2025.
  • Over 5 years, Common Equity stood at $73.5 million in 2021, then dropped by 9.61% to $66.5 million in 2022, then tumbled by 45.28% to $36.4 million in 2023, then grew by 5.03% to $38.2 million in 2024, then tumbled by 79.5% to $7.8 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $7.8 million, $13.8 million, and $19.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.